Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05870956 · ClinicalTrials.gov registry record
Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 1,798
- Enrollment target
NCT05870956: Completed study, sponsored by Boehringer Ingelheim.
NCT05870956 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,798 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05870956 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 1,798 participants
- Enrollment target
Study Summary
This study has two objectives: 1. To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient hospitalization, among patients with Idiopathic Pulmonary Fibrosis (IPF). 2. To assess the association between a patient's nintedanib adherence trajectory group (as measured from a GBTM) and their medical costs among patients with IPF.
Primary Outcome
Total all-cause medical costs per patient calculated as the sum of the total amounts paid for all medical services by the payer and the patient. The types of medical services covered by Medicare included inpatient facility, outpatient facility, skilled nursing facility, home health care, hospice, durable medical equipment, clinician office visits, and other physician services covered under the Part B benefit. The costs with prescriptions covered under Part D benefit were excluded from this outco
Interventions
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,798 participants |
| Start Date | 2023-05-16 |
| Est. Completion | 2023-06-30 |
What the finished NCT05870956 record still lists
NCT05870956 is an observational study that tracks outcomes without assigning an intervention. Its 1,798 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Nintedanib is the first listed.
NCT05870956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05870956 about?
NCT05870956 is a clinical study titled "Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients". This study has two objectives: 1. To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient hospitalization, among patients with Idiopathic Pulmonary Fibrosis (IPF). 2....
What is the current status of trial NCT05870956?
This trial is currently completed. The enrollment target is 1,798 participants. The study started on 2023-05-16. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05870956?
The interventions under investigation include: Nintedanib (DRUG).
Who is sponsoring clinical trial NCT05870956?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI